HCV Neutralizing Antibody Deconvolution via Pseudoparticle Panels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing antibody response to hepatitis C virus (HCV) vaccines are inaccurate, and there is a lack of understanding of correlates of protective immunity, hindering the development of effective HCV vaccines, with existing treatments being costly and not preventing reinfection after cure.
Innovation Solution
A high-throughput method is developed to deconvolute polyclonal anti-HCV neutralizing antibodies in plasma, identifying epitope specificities and correlating them with neutralization profiles to determine the contribution of individual antibodies, allowing for the identification of broadly neutralizing antibody combinations associated with HCV clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to assess antibody response to HCV vaccines, then the process is simple, but the accuracy is insufficient and there is lack of understanding of correlates of protective immunity
Solution Approach 1:
The patent segments the complex task of assessing antibody response into multiple measurable components by using a panel of HCV pseudoparticles representing different viral genotypes and epitopes. Each antibody's neutralization profile is measured across multiple particles, and the data is deconvoluted to identify specific epitope specificities, transforming a single vague measurement into multiple precise, actionable data points.
Solution Approach 2:
The patent introduces HCV pseudoparticles as intermediary elements that facilitate the measurement of antibody neutralization. These pseudoparticles serve as a controlled, measurable proxy for actual HCV infection, allowing laboratory-based assessment of antibody function without requiring complex in vivo infection models or ethical constraints.
2Reliability
If existing treatments are used, then HCV infection can be treated, but the cost is high and reinfection occurs after cure
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing broadly neutralizing antibodies (bNAbs) and their epitope specificities before vaccine deployment. By deconvoluting plasma samples from HCV-clearing individuals and measuring neutralization profiles against a comprehensive pseudoparticle panel, the research pre-determines which antibody responses correlate with protective immunity and viral clearance, enabling rational vaccine design that induces these protective responses.
Solution Approach 2:
The patent establishes feedback loops by measuring neutralization profiles of vaccine-induced antibodies against a standardized panel of HCV pseudoparticles and comparing results against established correlates of protective immunity. This feedback mechanism allows continuous optimization of vaccine formulations to ensure they induce antibody responses that reliably prevent reinfection, while cost-effectiveness can be monitored through reduced treatment needs.
Data Source
AI summary
Provided herein are, inter alia, methods, compositions and kits for HCV antigen and vaccine design. Preferred methods include measuring neutralization of HCV pseudoparticles (HCVpp) by antibodies specific for an HCV in the biological sample, generating a neutralizations profile of each biological sample; deconvoluting the HCV-specific neutralizing antibodies by generating reference antibody neutralization profiles; correlating the reference antibody neutralization profiles to the biological sample's neutralization profile; and, identifying the HCV neutralizing antibodies.